{"meshTagsMajor":["Lymph Node Excision","Mastectomy"],"meshTags":["Axilla","Breast Neoplasms","Female","Humans","Lymph Node Excision","Mammaplasty","Mastectomy","Neoplasm Staging","Radiotherapy"],"meshMinor":["Axilla","Breast Neoplasms","Female","Humans","Mammaplasty","Neoplasm Staging","Radiotherapy"],"organisms":["6755","9606"],"publicationTypes":["Journal Article","Practice Guideline"],"abstract":"Breast cancer is the most common malignancy in women in the United States and is second only to lung cancer as a cause of cancer death. The overall management of breast cancer includes the treatment of local disease with surgery, radiation therapy, or both, and the treatment of systemic disease with cytotoxic chemotherapy, endocrine therapy, biologic therapy, or combinations of these. This portion of the NCCN Guidelines discusses recommendations specific to the locoregional management of clinical stage I, II, and IIIA (T3N1M0) tumors. ","title":"Breast Cancer Version 2.2015.","pubmedId":"25870381"}